Chromosomal Instability in Ovarian Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-26

Study Completion Date

2024-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure. The changes rang from point mutation to small-scale genomic change and even the change of whole chromosome number. It has been reported that the characteristics of genomic rearrangement can be used as a marker of clinical outcome of high-grade serous ovarian cancer, and specific genomic rearrangement are related to the poor prognosis. In noninvasive gene detection with low coverage, patients diagnosed with ovarian cancer have deteriorating progression-free and overall survivals regardless of the tumor stage when somatic copy number distortion (sCNA) exceeds the threshold in plasma. The detection rate of sCNA increased along with the tumor stage. We enrolled those as our target patients, who are diagnosed with high-grade serous ovarian cancer and willing to take part in. The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment. Our aim is to explore the application of CIN in peripheral tumor DNA in the detection of minimal residual lesions (MRD) after primary treatment and recurrence monitoring.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

NCT04190667

Epithelial Ovarian Cancer Chinese Homologous Recombination Deficiency +3 more

UNKNOWN

Studying Chromosomes in Samples From Younger Patients With Neuroblastoma

NCT01589341

Neuroblastoma

COMPLETED

Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma

NCT06521684

Endometrial Neoplasms TP53 Gene Mutation Chromosomal Instability +1 more

NOT_YET_RECRUITING

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

NCT04651920

Epithelial Ovarian Cancer Chinese Homologous Recombination Deficiency +4 more

COMPLETED

Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma

NCT05845554

Biliary Tract Carcinoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epithelial Ovarian Cancer High-grade Serous Ovarian Carcinoma Chromosomal Instability Somatic Copy Number Distortion Survival Outcomes Minimal Residual Lesions Progression-free Survival Overall Survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Testing for chromosomal instability (CIN)

The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed of primary ovarian high grade serous carcinoma (HGSC)
* Aged 18 years or older
* Acceptance of surgical treatment for HGSC
* With detailed follow-up outcomes

* Declining to anticipate the trial

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No